tyvense 50 mg capsules, hard
takeda pharmaceuticals international ag ireland branch - lisdexamfetamine dimesylate - capsule, hard - psychoanaleptics
tyvense 60mg capsules, hard
takeda pharmaceuticals international ag ireland branch - lisdexamfetamine dimesylate - capsule, hard - centrally acting sympathomimetics
tyvense 70 mg capsules, hard
takeda pharmaceuticals international ag ireland branch - lisdexamfetamine dimesylate - capsule, hard - psychoanaleptics
elvanse 70 mg hard caps.
takeda pharmaceuticals international ireland branch ag - lisdexamfetamine dimesylate 70 mg - eq. dexamfetamine 20,8 mg - capsule, hard - 70 mg - lisdexamfetamine dimesylate 70 mg - lisdexamfetamine
tyvense 30 milligram capsules hard
shire pharmaceutical contracts ltd - lisdexamfetamine dimesylate - capsules hard - 30 milligram - 06ba12
tyvense 70 milligram capsules hard
shire pharmaceutical contracts ltd - lisdexamfetamine dimesylate - capsules hard - 70 milligram - 06ba12
tyvense 50 milligram capsules hard
shire pharmaceutical contracts ltd - lisdexamfetamine dimesylate - capsules hard - 50 milligram - 06ba12
tyvense 20 milligram capsules hard
shire pharmaceutical contracts ltd - lisdexamfetamine dimesylate - capsules hard - 20 milligram - phenylethylamine derivatives - centrally acting sympathomimetics - it is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (adhd) in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate
tyvense 40 milligram capsules hard
shire pharmaceutical contracts ltd - lisdexamfetamine dimesylate - capsules hard - 40 milligram - phenylethylamine derivatives - centrally acting sympathomimetics - it is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (adhd) in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate
tyvense 60 milligram capsules hard
shire pharmaceutical contracts ltd - lisdexamfetamine dimesylate - capsules hard - 60 milligram - phenylethylamine derivatives - centrally acting sympathomimetics - it is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (adhd) in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate.